- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | H.C. Wainwright reiterates Alpha Tau Medical stock rating at buy | 1 | Investing.com | ||
| Di | Alpha Tau rises on Alpha DaRT head and neck cancer data | 2 | Seeking Alpha | ||
| Di | Alpha Tau reports positive trial results for cancer therapy combo | 4 | Investing.com | ||
| ALPHA TAU MEDICAL Aktie jetzt für 0€ handeln | |||||
| Di | Alpha Tau meldet positive Studienergebnisse für kombinierte Krebstherapie | 1 | Investing.com Deutsch | ||
| Di | Alpha Tau Medical Ltd.: Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, ... | 197 | GlobeNewswire (Europe) | - Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT in combination with pembrolizumab... ► Artikel lesen | |
| 17.07. | H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment | 1 | Investing.com | ||
| 17.07. | H.C. Wainwright bestätigt Rating für Alpha Tau Medical nach Behandlungserfolg bei immunsupprimierten Patienten | 2 | Investing.com Deutsch | ||
| 15.07. | Alpha Tau Medical Ltd.: Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center | 202 | GlobeNewswire (Europe) | - The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which... ► Artikel lesen | |
| 15.07. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.06. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.06. | Alpha Tau Medical Ltd.: Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT at Hadassah University Medical Center in Israel | 336 | GlobeNewswire (Europe) | - First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world's... ► Artikel lesen | |
| 15.06. | H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA trial clearance | 1 | Investing.com | ||
| 15.06. | H.C. Wainwright bestätigt Kaufempfehlung für Alpha Tau Medical nach FDA-Zulassung für Studie | 1 | Investing.com Deutsch | ||
| 11.06. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.06. | Alpha Tau Medical Ltd.: Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control | 501 | GlobeNewswire (Europe) | - Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining... ► Artikel lesen | |
| 03.06. | Alpha Tau teams with Tolmar on lucrative prostate cancer deal | 1 | Globes | ||
| 03.06. | Alpha Tau Medical Ltd.; Tolmar Inc.: Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT Therapy to U.S. Urological Cancer Patients | 2 | GlobeNewswire (USA) | ||
| 03.06. | H.C. Wainwright bestätigt Kaufempfehlung für Alpha Tau Medical nach Studiendaten | - | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial data | 1 | Investing.com | ||
| 01.06. | Alpha Tau Medical Ltd.: Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting | 585 | GlobeNewswire (Europe) | - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of... ► Artikel lesen |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATOSSA THERAPEUTICS | 2,220 | +2,78 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants
SEATTLE, June 12, 2026 /PRNewswire/... ► Artikel lesen | |
| BUTTERFLY NETWORK | 5,695 | -1,76 % | Michael Burry sagt nur: wow: Butterfly +56 %: Die kleine Aktie hinter Midjourneys 60-Sekunden-Körperscanner | © Foto: Jaque Silva - NurPhotoMidjourney plant einen 60-Sekunden-Körperscanner per Ultraschall und KI. Butterfly liefert die Technik für den Prototyp. Anleger haben die Aktie am Donnerstag brutal hochgekauft... ► Artikel lesen | |
| BEYOND AIR | 5,430 | -5,07 % | XFRA 48L: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBEYOND AIR INC.... ► Artikel lesen | |
| AXOGEN | 34,890 | +1,16 % | NZS Capital Added Axogen (AXGN) as an Optionality Position | ||
| AETHLON MEDICAL | 0,600 | -0,10 % | Aethlon Medical, Inc.: Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier | Second cohort findings consistent with previously reported observations; independent statistical analysis planned following completion of all three patient cohorts
... ► Artikel lesen | |
| TACTILE SYSTEMS TECHNOLOGY | 23,480 | -2,90 % | Tactile Systems Technology, Inc.: Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026 | ||
| AVANOS MEDICAL | 21,600 | -1,82 % | AVANOS MEDICAL, INC. - 8-K, Current Report | ||
| HYDREIGHT TECHNOLOGIES | 2,730 | -1,09 % | Hydreight Technologies Inc.: Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working Capital | Revenue increased 449% year-over-year while the Company continued to scale its healthcare infrastructure platform.
VANCOUVER, BC and LAS VEGAS, June 1, 2026 /PRNewswire/... ► Artikel lesen | |
| ANGIODYNAMICS | 11,700 | -3,31 % | H.C. Wainwright raises AngioDynamics stock price target on growth | ||
| APYX MEDICAL | 3,780 | +10,53 % | Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 | ||
| ANTERIS TECHNOLOGIES GLOBAL | 8,190 | 0,00 % | ANTERIS TECHNOLOGIES GLOBAL CORP.: Notification regarding unquoted securities - AVR | ||
| ADAPTHEALTH | 10,475 | +0,05 % | Cardinal Health To Buy AdaptHealth's Diabetes Unit, Strive Medical For $360 Mln Total | WASHINGTON (dpa-AFX) - Healthcare services company Cardinal Health, Inc. (CAH) announced late Monday its agreement to acquire the Diabetes Health business of AdaptHealth Corp. (AHCO), as well... ► Artikel lesen | |
| BLUEJAY DIAGNOSTICS | 1,140 | 0,00 % | Bluejay Diagnostics, Inc.: Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study | ACTON, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today... ► Artikel lesen | |
| ADVANCED BIOMED | 16,720 | +36,49 % | Morning Market Movers: InMed Pharmaceuticals, INLIF Limited, China SXT Pharmaceuticals, Advanced Biomed See Big Swings | BEIJING (dpa-AFX) - At 8:30 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| AGAPE ATP | 2,550 | -1,16 % | Agape ATP Corp - S-1/A, General form for registration of securities |
Das Unternehmen ALPHA TAU MEDICAL LTD kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,84 % bei einem Aktienkurs von 13,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TAU MEDICAL LTD finden Sie auf Wallstreet Online.